Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.

PLoS One · 2016 · PMC4777410 · PMID 26937956

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

There were highly significant changes to the use of novel agents over time (see Table 2 ) where an increase in the use of both bortezomib, lenalidomide and thalidomide, (from 2005 onwards) and their simultaneous use in combination therapies (from 2010 onwards) could be observed.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.